Your session is about to expire
← Back to Search
Cohort 1 (first 60 subjects) PHV02 high dose for Nipah Virus
Study Summary
This trial is testing a new vaccine called PHV02 in healthy adults. The trial wants to find out what doses of PHV02 are safe and well-tolerated, and what the immune response
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Am I eligible to enroll in this medical research study?
"To be considered for enrollment in this clinical trial, prospective participants must have a confirmed diagnosis of Nipah virus and fall within the age range of 18 to 59. A total of 120 individuals will be accepted into the study."
Are researchers currently accepting participants for this study?
"Indeed, the information provided on clinicaltrials.gov indicates that this trial is currently in the recruitment phase. It was initially posted on February 1st, 2024 and last updated on January 15th, 2024. The study aims to enroll a total of 120 participants across three different sites."
How large is the participant pool in this research endeavor?
"To successfully execute this clinical trial, a total of 120 eligible participants who meet the inclusion criteria are required. Public Health Vaccines LLC, the sponsor of the study, will administer and oversee the trial across multiple sites. These include Cenexel ACT (Anaheim Clinical Trials) located in Anaheim, California, as well as Cenexel JBR (JBR Clinical Research) situated in Salt Lake City, Utah."
Are individuals above the age of 40 eligible to participate in this medical study?
"This trial is actively seeking individuals who are above 18 years old but below 59 years old to participate."
Has the PHV02 medium dose been granted approval by the FDA for Cohort 2, comprising the next 60 participants?
"Based on the nature of this Phase 1 trial, our team at Power assesses the safety of PHV02 medium dose in Cohort 2 (consisting of the next 60 participants) to be a score of 1. This is due to limited available data supporting both safety and efficacy."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger